The case: A patent case relating to prolonged release pharmaceutical formulations in which the active ingredient melatonin is intended to improve the restorative quality of sleep in a patient suffering from primary insomnia characterised by non-restorative sleep. The case called for experts in sleep medicine.

To continue reading you must be an EWI member, become a member and access exclusive content. 

Already a member? Login